Article
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
BMC cancer - 12 Aug 2016
Maleka A, Åström G, Byström P, Ullenhag G J
Abstract excerpt
BACKGROUND: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.